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TherapyDuchenne muscular dystrophy is caused by mutations that prevent synthesis of functional dystrophin. All
patients develop dilated cardiomyopathy. Promising therapeutic approaches are underway that successfully
restore dystrophin expression in skeletalmuscle.However, their efﬁciency in the heart is limited. Improved quality
and function of only skeletal muscle potentially accelerate the development of cardiomyopathy. Our study aimed
to elucidate which dystrophin levels in the heart are required to prevent or delay cardiomyopathy in mice.
Heart function and pathology assessed with magnetic resonance imaging and histopathological analysis were
compared between 2, 6 and 10-month-old femalemdx-XistΔhs mice, expressing low dystrophin levels (3–15%)
in a mosaic manner based on skewed X-inactivation, dystrophin-negative mdx mice, and wild type mice of
corresponding genetic backgrounds and gender.
With agemdxmice developed dilated cardiomyopathy and hypertrophy, whereas the onset of heart pathology
was delayed and function improved inmdx-XistΔhsmice. The ejection fraction, themost severely affected param-
eter for both ventricles, correlated to dystrophin expression and the percentage of ﬁbrosis. Fibrosis was partly
reduced from 9.8% inmdx to 5.4% in 10 month old mdx-XistΔhs mice.
These data suggest that mosaic expression of 4–15% dystrophin in the heart is sufﬁcient to delay the onset and
ameliorate cardiomyopathy in mice.
© 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY license. 1. Introduction
Duchenne muscular dystrophy (DMD) is the most common
inherited neuromuscular disorder. In DMD patients, the synthesis of
functional dystrophin proteins is prevented by mutations in the DMD
gene [1]. Dystrophin negative ﬁbers are vulnerable to exercise-
induced damage, leading to loss of ambulation in the second decade
of life. Cardiomyopathy is increasingly observed from 10 years of age
onwards [2]. Old patients depend on assisted ventilation and at that
stage the vastmajority suffers from dilated and hypertrophic cardiomy-
opathy of the left ventricle, while the right ventricle and atrium remain
unaffected [3,4]. Eventually, patients die of heart or respiratory failure in
their third or fourth decade [5].
Beckermuscular dystrophy (BMD) patients have in-framemutations
in the DMD gene, resulting in expression of internally deleted, but partly
functional dystrophins. The skeletalmuscle pathology is less severe than
in DMD patients, but a more severe cardiomyopathy is observed,MD, Beckermuscular dystrophy.
etics, Leiden University Medical
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.Open access under CC BY license. especially in BMD patients with a mild muscle phenotype, accounting
for 50% of deaths [3,6,7]. Dilated cardiomyopathy is also occasionally
found in DMD and BMD carriers, who express 50% of dystrophin in the
heart [8].
There is no cure for DMD, but several potential therapies aiming at
dystrophin restoration are under investigation in clinical trials [9–13].
Unfortunately, the efﬁciency of targeting the heart is limited. Eventually,
this might result in partial dystrophin restoration in skeletal muscle,
accompanied by improvedmuscle function, in the absence of restoration
in the heart [14–16]. Given that BMD patients and some DMD/BMD
carriers exhibit more pronounced cardiomyopathy than DMD patients,
increased physical activity is likely to put a larger workload on the
heart, thereby potentially exacerbating the development of cardiomyop-
athy, although other factors, like competition between utrophin and
dystrophin, might also play a role.
Thedystrophin-negativemdxmouse also suffers fromdilated cardio-
myopathy, of which the progression is accelerated by activity [17–21]. In
linewith this, partial dystrophin restoration in skeletalmuscle improves
voluntary activity, increasing the heart workload and exacerbating heart
pathology [15]. By contrast, high dystrophin levels in skeletal muscles
and diaphragm only, either improve heart function in 6 month old
mice [22], or prevent worsening of heart failure in exercise challenged
23 month oldmdxmice [23]. In addition, an internally deleteddystrophin
(mini-dystrophin) transgene has been delivered to the heart using adeno
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preventedmyocardial ﬁbrosis, especially whenmice were treated before
they were 17 months [24,25].
From carrier mdx mice, it is known that 50% of dystrophin in the
heart is sufﬁcient to prevent development of heart pathology [26]. To
study whether low dystrophin levels are enough to prevent or delay
the onset of heart failure, we assessed heart function and pathology
over time inmdx-XistΔhsmice. Thesemice originate fromcrossingXistΔhs
females (expressingwild type dystrophin but carrying amutation in the
promoter of the Xist gene, which coordinates X-inactivation [27]), with
mdx males (which do not express dystrophin and have a normal Xist
gene). In the female offspring (mdx-XistΔhs), the X-chromosome
expressing themutated Xist gene, but intact dystrophin, is preferentially
inactivated, resulting in expression of varying, low dystrophin levels in
skeletal muscle and heart [28]. We show that mosaic expression of
dystrophin in 4–15% of the cardiomyocytes (at wild type intensities) is
sufﬁcient to delay the onset of dilated cardiomyopathy and reduce the
severity of pathology inmdxmice.
2. Methods
2.1. Animal care
Breeding pairs of mdx (C57BL/10ScSn-mdx/J) males and XistΔhs
females (BL/6 background) gave birth to mdx-XistΔhs females [28].
The XistΔhs model [27] was a kind gift from prof. Dr. Brockdorff (MRC
Clinical Sciences Centre London, UK, current afﬁliation Department of
Biochemistry, University of Oxford, UK). Genotyping was performed
on DNA obtained from ear biopsies by PCR analysis. Mice were housed
in individually ventilated cages with 12-h light-dark cycles and had ad
libitum access to standard chow and water. All experiments were
approved by the Animal Experimental Commission (DEC) of the LUMC
and conformwith the Directive 2010/63/EU of the European Parliament.
2.2. MRI heart function analysis
MRI analysiswas performed at the Faculty of Science of theUniversity
of Leiden to which the mice were transported a week before analysis to
acclimatize. Mice were anesthetized by inhalation of 2% isoﬂurane in a
1:1 mixture of pure oxygen and air. Respiration rate was monitored
with a respiratory pad and kept constant at 50–80 respirations per min-
ute. Mice were scanned in a vertical 9.4 T magnet with 89 mm bore size,
equipped with a 1 T/m gradient system (Bruker BioSpin, Germany),
using a quadrature birdcage coil (inner diameter 3 cm). Image acquisi-
tion was done with Bruker Paravision 5.0 software and took ~30 min
including animal setup. A retrospectively-gated Intragate sequence was
used with ﬂip angle 10°; repetition time 8.5 ms; echo time 1.86 ms;
ﬁeld-of-view 2.56 × 2.56 cm2;matrix 192 × 192; and in-plane resolution
133 μm. We made 8–9 short-axis slices of the heart of 1 mm thick and
200 repetitions per slice. The navigator echo was placed in-slice.
Images were reconstructed to 18 frames per heart cycle. Per time point
27 mdx-XistΔhs mice and six mice of the control groups were scanned.
Six of the 135 mice scanned were not used for analysis as the angle of
the scan was incorrect.
MASS for MICE software (developed at the LUMC, Division of Image
Processing (LKEB)) was used for image analysis [29]. For each picture,
endocardial and epicardial contours of both ventricles were drawn
manually. The end diastolic and systolic phase were computed by the
software and a maximum mass difference of 10% was accepted. When
this criteria was met, end diastolic volume (EDV) and end systolic
volume (ESV) were determined and based on these values stroke
volume (SV = EDV-ESV), ejection fraction (EF = (SV/EDV)*100%)
and cardiac output (CO= SV*heart rate)were calculated automatically.
Left ventricular end diastolic thickness and end systolic wall thickening
were measured for the mid-section of the heart.2.3. Serum biomarker level analysis
For analysis of cardiac Troponin I andN-terminal Pro BrainNatriuretic
Peptide (NT-proBNP) levels, blood (~1ml)was drawn from the anesthe-
tized mouse via the eye after which animals were sacriﬁced by cervical
dislocation. Bloodwas collected in a non-coated eppendorf tube, allowed
to clot at room temperature for 10 min and stored on ice. Samples were
centrifuged at 1700 g for 10 min at 4 °C and stored at−80 °C. Levels of
cardiac Troponin I and NT-proBNP were measured using the High
Sensitive Mouse Cardiac Troponin-I ELISA Kit (Life Diagnostics, USA)
and the ELISA Kit for NT-proBNP (Uscn Life Science Inc., China),
respectively.
2.4. Histological examination
Tissues were snap frozen in 2-methylbutane (Sigma Aldrich, the
Netherlands) cooled in liquid nitrogen. Sections of 8 μm were made
on Superfrost Plus slides (Thermo Fishes Scientiﬁc, Menzel-Gläser,
Germany) with a Shandon cryotome (Thermo Fisher Scientiﬁc Co.,
USA) along the entire length of the heart with an interval of 240 μm
between the sections. Excess tissue was used for protein isolation.
Sections were stained with goat-anti-Collagen type 1 (dilution 1:100,
1310-01 Southern Biotech, USA), donkey-anti-goat Alexa594 (dilution
1:1000, Invitrogen, the Netherlands) and DAPI. A ﬂuorescent micro-
scope (Leica DM RA2) was used to examine the sections at a 16 times
magniﬁcation and images covering the entire heart were captured
with a LeicaDC350FX snapshot camera. The percentage of ﬁbrotic tissue
was assessedwith ImageJ software (RasbandW.S., ImageJ, U.S. National
Institutes of Health, USA, http://rsb.info.nih.gov/ij/, 1997–2008). The
number of arterioles, cardiomyocyte size and distribution of ﬁbrosis
were determined on sections stained with Harris Haematoxylin and
Eosin (Sigma Aldrich, the Netherlands), which were examined with a
light microscope (Leica SP5, Leica Microsystems, United Kingdom).
The minimal Feret's diameter of the cardiomyocytes was measured
with ImageJ software on four pictures taken at a 40 timesmagniﬁcation.
The severity of ﬁbrosis, ranked into six categories, was assessed for ten
regions to assess its distribution.
2.5. Dystrophin determination by western blot
The heart, diaphragm and quadriceps muscles were homogenized
and dystrophin levels quantiﬁed by western blotting using the Odyssey
system as described previously [28]. The lowest concentration in the
standard curve was 3%. Blots were stained overnight with NCL-DYS1
(dilution 1:125, Novacastra, UK) and MF20 (MF20 dilution 1:20000,
Developmental Studies Hybridoma Bank, University of Iowa, Iowa
City) for dystrophin and myosin respectively. The ﬂuorescent IRDye
800CW goat-anti-mouse IgG (dilution 1:5000, Li-Cor, USA) was used as
secondary antibody.
2.6. Statistics
Statistical analyses were performed using SPSS 17.0.2. (SPSS, Inc.,
USA). Heart functionwas compared over timewith the two-way analysis
of variance (ANOVA). In case of signiﬁcance (P b 0.05), a Fisher’s Least
Signiﬁcant Difference-procedure (LSD) was applied to distinguish
between heart function of different strains and to analyze within a
mouse strain whether there are differences in heart function over time
(so between 2, 6 and 10 month oldmice). For ESVdata, a log transforma-
tion was performed to correct for inequality of the data. Correlations for
the 10-month-oldmdx-XistΔhs mice were tested with the Spearman cor-
relation test. P b 0.05 was considered signiﬁcant. The one-way ANOVA
was conducted for comparison of the histological and wall thickness
data. In case of signiﬁcance (P b 0.05), the Bonferroni post hoc test was
performed. For Fig. 1B, data are presented as medians.
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3.1. Low dystrophin levels in the heart prevent the age-dependent decline of
heart function
To determine whether low dystrophin levels can prevent or delay
the onset of dilated cardiomyopathy, heart function was determined
by MRI in female mdx (no dystrophin), mdx-XistΔhs (low dystrophin),
C57BL/10ScSnJ (wild type) and XistΔhs (wild type) mice aged 2, 6 and
10 months. We chose a cross-sectional design to allow post-mortem
histological validation. Dystrophin was expressed in a mosaic manner
in the hearts of mdx-XistΔhs mice, where cardiomyocytes were either
dystrophin positive at wild type intensities or negative as previously
reported [28] (Supplementary Figure A). Dystrophin levels in the
heart of mdx-XistΔhs mice varied between 3 and 15% and were similar
for the different age groups (2 months; 3–13.8%, 6 months; 3–14.9%,
10 months; 3–12.1%) as assessed by western blot (Figs. 1A–B).
The heart function of the two wild type models was largely compa-
rable, but differed slightly, probably due to differences in the genetic
background. In 2 month oldmdxmice ejection fraction (EF) is stronger
than that of wild type mice. With age, function of both ventricles dete-
riorated, most evidently for the (EF) and stroke volume (SV), while it
remained constant in bothwild typemodels (Figs. 1C–D, Supplementary
Table A), as reported previously [30]. Expression of 3–15% dystrophin in
the heart prevented EF and SV to drop in mdx-XistΔhs mice as levels
remained stable over time and were higher than mdx mice from the
age of 6 months onwards (P b 0.05). The EF and SV of mdx-XistΔhs
mice were similar to levels of the wild type stains at 6 months, and
for the left ventricle only lower than 10-month-old XistΔhs mice
(P b 0.05). The end systolic volume (ESV) of the left ventricle wasFig. 1.Dystrophin levels and heart function ofmdx-XistΔhs mice. (A) Dystrophin levels were ass
was used as a loading control. M= marker. (B) Dystrophin levels plotted in the box plot. The li
quartile. The bars show maximum and minimum values considered excepting outliers (indica
increment was observed in older animals. (C) The EF of the left ventricle remained stable in
whichwas prevented inmdx-XistΔhsmice. (D) The SV of the left ventriclewas lower in oldmdxm
Asterisks indicate a difference of P b 0.05. Asterisks without brackets indicate a difference bet
Sample sizes are indicated in the bars.increased in 10-month-old mdx mice (P b 0.01), while levels of mdx-
XistΔhs mice remained similar to wild types. The end diastolic volume
(EDV) and cardiac output (CO) of both ventricles and ESV of the right
ventricle did not differ between the mouse models.
End systolic mass of both ventricles increased with age in all mice.
However, the left ventricular mass of mdxmice was greater than that
of all other mice regardless of their age (P b 0.01), indicative of hyper-
trophy of the heart. This was not observed for mdx-XistΔhs mice. The
minimal Feret's diameter of cardiomyocytes showed a similar pattern,
and tended to be larger in 10-month-old mdx than C57BL/10ScSnJ
mice (P = 0.056, Supplementary Table B). The left ventricular lateral
freewall thickness in diastolewas larger inXistΔhs than the othermodels
aged 10 months (P b 0.05 Supplementary Table B), while thickening
in systole was larger in XistΔhs compared to both dystrophic models
(P b 0.01). For both parameters no differencewas observed in the inter-
ventricular septum.
Heart rate increased inmdxmicewith age (P b 0.001), but remained
stable over time for the other models. Heart rate of 2-month-old XistΔhs
mice was higher than that of bothmdx andmdx-XistΔhs mice (P b 0.01).
In oldmdxmice, heart rate exceeded bothmdx-XistΔhs and XistΔhs mice
(P b 0.01).
Dystrophin levels of 10-month-oldmdx-XistΔhs mice correlatedwith
the EF of the left ventricle (R = 0.464 P= 0.019), which was also the
most severely affected parameter in mdxmice (Fig. 2A). As heart func-
tion has been described to normalize by dystrophin expression in the
diaphragm [22], we also assessed this for 10-month-old mdx-XistΔhs
mice. Dystrophin levels of the diaphragm varied between 1.5 and 38%
(mean= 11.5% stdev= 8.8) and did not correlate to dystrophin levels
in the heart (R = 0.04 P= 0.849). Dystrophin levels in the diaphragm
only correlated with the EDV of the right ventricle (R = 0.492 P =essed by western blot for allmdx-XistΔhs mice, as shown in the representative blot. Myosin
ne dissecting the box resembles themedian and outer bars resemble the lower and upper
ted by○). Dystrophin levels varied between 3 and 15%, n= 27 for all age groups, and no
wild type mice, but declined (P b 0.01) in mdxmice from the age of 6 months onwards,
ice thanof XistΔhs andmdx-XistΔhs. Bars representmean values and the standarddeviation.
ween that group and all other groups. $ indicates difference within that strain over time.
Fig. 2. Correlation between dystrophin expression and heart function. (A) Dystrophin levels of the heart correlated to EF of the left ventricle in 10-month-oldmdx-XistΔhsmice (R= 0.464
P = 0.019). (B) b4% dystrophin in the heart did not restore EF despite dystrophin expression in the diaphragm. EF levels were improved in mice expressing N4% dystrophin in the heart
regardless of expression levels in the diaphragm. H = heart, D = diaphragm. Bars represent mean values and the standard deviation. Asterisks indicate a difference of P b 0.05. Sample
sizes are indicated in the bars.
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hypothesized that the combined presence of dystrophin in the heart
and diaphragm might have a cumulative beneﬁcial effect on heart func-
tion (Fig. 2B). To study this, we grouped the EF of 10-month-old mdx-
XistΔhs mice based on their dystrophin levels in the heart and diaphragm
into the following groups; mice with b4% dystrophin in the heart and
N4% in diaphragm (heart;median 3.0% stdev= 0.29, diaphragm;median
8.67% stdev= 3.07), N4% dystrophin in the heart and b4% in diaphragm
(heart; median 7.64% stdev= 1.13, diaphragm; median 2.63% stdev =
0.88) and N4% dystrophin in the heart and diaphragm (heart; median
6.31% stdev = 3.04, diaphragm; median 15.23% stdev = 9.31) (there
were no mice with b4% dystrophin in both heart and diaphragm). The
EF of both ventricles of mice expressing b4% dystrophin in heart and
N4% in diaphragm was as low as age-matched mdx mice. The EF of
mice expressing N4% dystrophin in heart and b4% or N4% in diaphragm
was higher than in mdxmice (P b 0.05). This indicates that the expres-
sion of N4% dystrophin in the heart only improves EF of both ventricles,
while expression of N4% (but less than 14%) dystrophin in diaphragm
only does not (data for the right ventricle are not shown).We performed
the same analysis for the quadriceps, but as for the diaphragm, no effect
of dystrophin levels in quadriceps on heart function was found (data not
shown).
We also assessed levels of potential serum biomarkers for heart
failure; cardiac Troponin I and N-Terminal Pro Brain Natriuretic Peptide
(NT-proBNP). Detectable concentrations of cardiac Troponin I were
observed for some mice for all models and at all ages, but were slightly
more often found in serumof dystrophicmice (Fig. 3A). Cardiac Troponin
I levels did not differ between mdx and mdx-XistΔhs mice, nor did they
correlate to heart dystrophin levels (R = 0.004 P = 0.986). Levels did
correlate to SV and CO of the right ventricle (R = −0.535 P = 0.015
and R=−0.483 P= 0.031 respectively). NT-proBNP levels were unde-
tectable in any of the mouse models at any age.
3.2. Low dystrophin levels partly reduce ﬁbrosis
Transverse cross-sections of the heart were stained with Collagen
type I, to determine thepercentage of ﬁbrotic tissue (see Supplementary
Figure B for representative examples). No ﬁbrosis was detected in 2-
month-old mice, whereas levels were slightly elevated in 6-month-old
mdx and mdx-XistΔhs compared to wild type mice (2.4% and 3.4% vs
2%, Fig. 3B). Due to high individual variation only the increment of the
mdx-XistΔhs mice reached signiﬁcance (P b 0.05). Fibrosis was most
prominent in 10-month-old mdx mice and was predominantly found
in the lateral wall of the left ventricle (Fig. 3C). Its formation was partly
prevented inmdx-XistΔhs mice (9.8% vs 5.4%, P b 0.01), although levels
were still higher than wild type (P b 0.01). Dystrophin levels in the
mdx-XistΔhs hearts did not correlate with ﬁbrosis (R = −0.234 P =
0.240, Fig. 3D). Fibrosis negatively correlated to the EF of the left ventricle(R = −0.512 P = 0.009) (Fig. 3E). This concurs with the above
described correlation between the EF and dystrophin levels. Heart
mass of the left ventricle did not correlate with ﬁbrosis (R = 0.253
P = 0.222). The number of arterioles did not differ between 10-month-
old mdx and wild type mice (mean number of arterioles ±stdev mdx
4.75± 3.46 vs C57BL/10ScSnJ 4.25 ± 2.25, XistΔhs 4.71 ±2.63, all groups
n= 6).
4. Discussion
Potential therapeutic strategies for DMD are currently tested in clini-
cal trials and encouraging results have beenpublished for dystrophin res-
toration in skeletal muscles [12,13]. Unfortunately, several therapeutic
approaches fail or are less efﬁcient in restoring dystrophin expression
in the heart [9–13]. It is unknown whether low dystrophin levels in the
heart can preserve function and prevent or delay heart pathology.
Weused skewedX-inactivation as a tool to generatemice expressing
low dystrophin levels in a mosaic manner in the heart and skeletal
muscles. Both C57BL/10ScSnJ and XistΔhs (BL/6 background) wild type
mice were investigated to eliminate potential strain effects. Heart func-
tion ofmdxmice progressively declines with age, resulting in dilation of
both ventricles in 10-month-old mice [18,19,30,31]. With age, themdx
heart becomesﬁbrotic, and genes involved in pathology are upregulated,
whereas this remains stable in wild type hearts [32,33]. Interestingly,
expression of 3–15% dystrophin in 10-month-oldmdx-XistΔhs mice ame-
liorates the age-dependent loss of heart function and pathology, as heart
function parameters, ﬁbrosis and hypertrophy partly normalize towards
wild type levels. Although EF was higher in 2 month oldmdx compared
to wild type mice levels, they fell within the normal range. From the age
of 6 months onwards, EF, SV and ESV are already affected in mdxmice,
while this is observed later (10 months) and to a lesser extent inmdx-
XistΔhs mice. We did not observe a decrease in CO, probably due to an
increased heart rate of themdxmice, which was higher than all models
except C57BL/10ScSnJ mice. This is likely due to the higher standard
deviation in that group caused by two mice (st.dev. 80 bpm for C57BL/
10ScSnJ while 40 bpm for the other models).
These data concur with a study we published recently involving a
more severe mouse model also lacking utrophin (mdx/utrn−/−/XistΔhs)
[34]. Expression of 4% dystrophin in skeletal muscle greatly improved
survival to over a year, whereas dystrophin and utrophin double knock-
out mice normally die before 12 weeks of age. Ejection fraction in
10 month old mdx/utrn−/−/XistΔhs mice with median heart dystrophin
levels of 4.3% was severely reduced, but partly normalized in mice
with median heart dystrophin levels of 29.7%. Here, we observe that
EF partly normalizes to wild type levels in 10 month old mdx-XistΔhs
mice expressing lower dystrophin levels (b15%), indicating that
utrophin-negative mice need higher dystrophin levels to improve car-
diomyopathy to a similar extent. This results most likely from the
Fig. 3. Cardiac Troponin I levels, ﬁbrosis and correlation between ﬁbrosis, dystrophin expression and heart function. (A) Serum cardiac Troponin I levels exceeded the detection threshold
of 0.2 ng/μl in some samples from all models. Levels did not differ between models or correlate to dystrophin expression in the heart (R = 0.004 P= 0.986). Sample sizes are indicated
below the bars. (B) The percentage of ﬁbrosis increases with age. While 10-month-oldmdxmice develop severe ﬁbrosis, low dystrophin levels partly prevent this. C57BL/10ScSnJ n= 9,
XistΔhs n= 6,mdx-XistΔhs n= 27,mdx n= 9 per time point. (C) Distribution of interstitial collagen deposits of 10-month-oldmdxmice based on ranking system. (D) Scatter plot of the
percentage ofﬁbrosis versus dystrophin levels of the heart of 10-month-oldmice. Althoughmdx-XistΔhsmice had lessﬁbrosis thanmdxmice, dystrophin levels did not correlate to ﬁbrosis
(R=−0.234 P= 0.240,mdx n= 9, C57BL/10ScSnJ n= 9, XistΔhs n= 6,mdx-XistΔhs n=27). (E) Fibrosis levels of 10-month-oldmdx-XistΔhs mice negatively correlated to EF of the left
ventricle (R=−0.512 P= 0.009). C57BL/10ScSnJ n=5, XistΔhs n=6,mdx-XistΔhs n=25,mdx n=5. Bars representmean values and the standard deviation. Asterisks indicate P b 0.05.
Asterisks without brackets indicate a difference between that group and all other groups.
21M. van Putten et al. / Journal of Molecular and Cellular Cardiology 69 (2014) 17–23protective effect of utrophin on theheart inmdxmice. Notably, there ap-
pears to be a threshold effect, where dystrophin levels b4% in the heart
are not effective to ameliorate heart failure, while levels between 4 and
15% dystrophin are.
It was hypothesized that the combined expression of dystrophin in
the heart and diaphragm might cumulatively improve heart function
[22]. This was based on observations in Fiona mice and PPMO treated
mdx mice expressing ~100% utrophin or dystrophin, respectively, in
skeletalmuscles. These high levels in diaphragmprevented heart failure
in 6 month old mice [22]. High levels of expression of a human mini-
dystrophin in diaphragmpreventedworsening of heart function caused
by increased activity in 23 month oldmdxmice [23]. We observed that
expression of 4–14% dystrophin in diaphragm does not improve heart
function (EF, themost affected parameter) inmdx-XistΔhsmice, whereas
similar levels in the heart do. Expression of N4% dystrophin in both the
heart and diaphragmdoes not further improve heart function indicating
that the cumulative beneﬁcial effect of dystrophin expression in dia-
phragm on heart function is limited. This is in line with observations
in PPMO treatedmdxmice, where increased voluntary activity deterio-
rated heart pathology, which could not be prevented by expression of
40–60% dystrophin in the diaphragm [15]. This indicates that this dis-
crepancy might be caused by the low dystrophin levels in diaphragmin Malerba's and our study compared to the high dystrophin levels in
the studies reported by Crisp [22] and Wasala [23]. This suggests that
for a protective effect on heart function probably high dystrophin levels
in diaphragm are needed.
Dystrophin levels of the mdx-XistΔhs mice do not correlate with
ﬁbrosis, whereas, ﬁbrosis correlates to the EF of both ventricles, which
is in concordance with literature [33]. It should be stressed that mdx-
XistΔhsmice also express lowdystrophin levels in skeletalmuscle leading
to improved muscle quality and function, which has been reported to
increase the workload for the heart, thereby potentially worsening
cardiomyopathy. We hypothesize that mice with dystrophin amounts
in skeletal muscle that are sufﬁcient to allow increased activity lead to
a higher workload for the heart resulting in high levels of ﬁbrosis,
while mice with low dystrophin levels in the muscle and heart are less
active, but still develop ﬁbrosis because the lower dystrophin levels
make the heart more sensitive even in an unstressed state. Whether
4–15% dystrophin in the heart is still protective when voluntary or
forced strenuous exercise is applied or when the heart is stressed by
drugs (e.g. dobutamine) remains to be elucidated.
It is good to bear in mind that,mdx-XistΔhs mice express dystrophin
from the embryonic stage onwards, whereas expression is normally
restored at post weaning age in gene therapy treated mdx mice,
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possible that the development of ﬁbrosis is linked to ischemia, e.g. due
to reduced capillary supply in the dystrophic heart. This was not
assessed in the current study. However, it is known that dystrophin neg-
ative ﬁbers are prone to damage and that the disposition and loss of
nNOS are playing big roles in the development of heart failure, so ische-
mia may contribute to the pathology but is probably not the main driver.
The hearts of mdxmice are hypertrophic from the age of 2 months
onwards, a pathological feature which is not observed in mdx-XistΔhs
mice. Our ﬁnding (assessing the mass of the entire ventricle) concurs
with the report of Costas et al. (assessing ventricular wall thickness for
a single point [20]), but is in contrast with work from others who
observe hypertrophy from 6 months onwards (measuring heart to
body weight ratios) [18,35]. The difference in age of onset might be
caused by differences in sensitivity of the quantiﬁcation methods
used. Unfortunately, we did not collect data on heart and body weight,
so it was not feasible to conﬁrm this.
The applicability of cardiac Troponin I and NT-proBNP as biomarkers
for heart failure was also assessed. Cardiac Troponin I has previously
beenused for detection of cardiac infarcts andwas reported to be a useful
marker for heart function in DMD and BMD patients [36]. Additionally,
cardiac Troponin I levels of idebenone treated mdx mice have been
reported to normalize towards wild type levels [37]. Unexpectedly, our
serum cardiac Troponin I values did not correspond with those obtained
by Buyse et al. However, personal communication revealed that these
values were in the pg/ml range instead of the published ng/ml, making
their observations fall in the same range. Although heart function of
mdx mice is impaired, serum cardiac Troponin I levels barely exceed
the detection threshold of the kit. Thus, we feel that the usefulness of
cardiac Troponin I as a biomarker for cardiomyopathy in dystrophic
mouse models is limited. Based on literature, the applicability of
NT-proBNP is questionable as well, as positive and negative correlations
with heart function in DMD and BMD patients have been published
[4,38]. In our hands, NT-proBNP levels in serum are undetectable even
in 10-month-old mdx mice. Therefore we propose that serum NT-
proBNP levels are not suitablemarkers for the assessment of heart failure
inmdxmice younger than 10 months.
Our study is partly limited by the fact that scans only entirely cover
the left ventricle, while the top part of the right ventricle is not scanned.
At initiation of this study, our primary focus was the left ventricle, but
with interesting ﬁndings published on the right ventricle meanwhile,
we also analyzed MRI data available for the right ventricle. All scans
were analyzed in the samemanner and up to the same height to ensure
comparability. Lacking the upper ~25% of the right ventricle resulted in
a lower CO for the right compared to the left ventricle. Itmay also be the
reason that we observe a more severe phenotype for the left than the
right ventricle, while others have reported the opposite [22,30].
Inherent to the mdx-XistΔhs model, only females of a mixed back-
ground were assessed. Gender is known to inﬂuence cardiac function
in animals and human. Female mdx mice aged 22 months develop
more pronounced cardiomyopathy than males [39]. We can only spec-
ulate whether similar dystrophin levels will be protective in male mice
as well. Since themdxmouse has a BL/10 background and the XistΔhs a
BL/6 background, the resulting females have a mixed background. We
therefore used two wild type models as controls, although we cannot
rule out that heart function is impacted differently by loss of dystrophin
in the two different backgrounds. An alternative strategy would have
been to use one of themdxcvmodels, as these are in a BL/6 background.
However, these models are not widely used and information on the
development of cardiomyopathy in thesemodels has only very recently
become available [40].
In summary, we have shown that expression of 4–15% dystrophin
not only delays the onset of cardiomyopathy, but also ameliorates its
severity in 10-month-old mdx mice. These observations suggest that
treatments restoring only low dystrophin levels in the heart of DMD
patients may have beneﬁts on heart function.Funding
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